John Forrest

Associate
Full contact info

Experience

Propella Therapeutics Enters Merger Agreement With Astellas Pharma

November 16, 2023

Cooley advised Propella Therapeutics, a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs, on its merger agreement with Astellas Pharma in which Astellas will acquire Propella through a US subsidiary.

Read more

Related contacts

Aaron Binstock
Partner, Washington, DC
Kenneth Krisko
Partner, Reston
Lindsey O'Crump
Associate, Washington, DC
Danielle Joe
Associate, Washington, DC
David Walsh
Partner, Reston
Xander Lee
Partner, Los Angeles Santa Monica
Megan Browdie
Partner, Washington, DC
Howard Morse
Partner, Washington, DC
Steve Tonsfeldt
Partner, Palo Alto
Christopher Kimball
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Mary Maher Lewis
Special Counsel, Reston
Stacey A. Bradford
Special Counsel, Washington, DC
Heather Harrington
Special Counsel, Boston
Stephanie Parker Palmer
Special Counsel, Reston
Stella Sarma
Special Counsel, Brussels
Sharon Connaughton
Special Counsel, Washington, DC
Dov Fiskus
Associate, New York
Richard G.S. Lee
Associate, Washington, DC
Jennifer Don
Associate, Reston
John Forrest
Associate, Boston
Kevin Milgram
Associate, Reston
Carly Mitchell
Partner, Washington, DC
Rick Jantz
Associate, Los Angeles Santa Monica
Virat Gupta
Associate, Washington, DC
Amanda Griggs
Associate, New York
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

Travere Sells Bile Acid Product Portfolio to Mirum

July 18, 2023

Cooley advised Travere Therapeutics, a biopharmaceutical company, on its definitive agreement to sell its bile acid product portfolio to Mirum Pharmaceuticals.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Charity Williams
Partner, San Diego
John Forrest
Associate, Boston
Melissa Meza
Associate, San Diego
Jacqueline Grise
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Amanda Griggs
Associate, New York
Jeffrey J. Tolin
Partner, New York
Ross Eberly
Partner, Los Angeles Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC
Peter Adams
Partner, San Diego
Rachel Thorn
Partner, New York
Alessandra Murata
Partner, Palo Alto
Cara Buchicchio
Associate, New York
Tony P. Guan
Associate, Los Angeles Santa Monica
Lei Shen
Partner, Chicago
Allison Kutner
Associate, New York
Loriane Sangaré-Vayssac
Associate, Brussels
Patrick Van Eecke
Partner, Brussels
Wyatt Kernell
Associate, New York
Asa Henin
Special Counsel, San Diego

Related Practices & Industries

Tmunity Therapeutics Agrees to Sell to Kite

December 28, 2022

Cooley advised Tmunity Therapeutics, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.

Read more

Related contacts

Mark Weeks
Partner, Palo Alto
Ben Beerle
Partner, San Francisco
Marya Postner
Partner, Palo Alto
Chen Chen
Associate, Palo Alto
Jenny Ge
Associate, Los Angeles Santa Monica
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Los Angeles Santa Monica
Todd Gluth
Partner, San Diego
Kate Hillier
Partner, Seattle
Phil Mitchell
Partner, New York
Howard Morse
Partner, Washington, DC
David Walsh
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington, DC
Stella Sarma
Special Counsel, Brussels
Andrew Bae
Associate, Washington, DC
Baasit Bhutta
Associate, Colorado
Paula Fleckenstein
Associate, Reston
John Forrest
Associate, Boston
Joyce Li
Associate, Chicago
Lindsey O'Crump
Associate, Washington, DC
Patrick Sharma
Associate, Los Angeles Santa Monica
Rubin Waranch
Associate, Washington, DC
Freddy Yip
Associate, Hong Kong

Related Practices & Industries

Nykode Therapeutics Enters Collaboration Agreement with Regeneron

November 24, 2021

Cooley advised Nykode Therapeutics in its license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases. 

Under the terms of the agreement, Nykode Therapeutics will receive a $30 million upfront payment and a $20 million equity investment at a premium of 20% on a 30-day volume weighted average price of the Nykode Therapeutics share for the last 30 trading days before the effective date of the agreement. Additionally, Nykode Therapeutics will potentially be eligible to receive more than $875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration, bringing the total potential value of the agreement to more than $925 million, plus royalties.

Lawyers Ken Krisko, Christophe Beauduin, John Forrest, Marya Postner and Hajra Nashin led the Cooley team advising Nykode. 

 

Related contacts

Christophe Beauduin
Special Counsel, New York
John Forrest
Associate, Boston
Marya Postner
Partner, Palo Alto

Related Practices & Industries